Metabolic Health Milestones: Adjusting as Markers Improve
A protocol built for insulin resistance is the wrong protocol once insulin sensitivity has been restored. What to remove, what to keep, and how to avoid losing the gains.
The Short Answer
Metabolic interventions succeed often enough that the question of what to do next is a real one, and it is usually unanswered. A person who has corrected insulin resistance, normalised triglycerides and lost visceral fat is in a different situation from the one their protocol was built for. Some components have done their job and can go. Others are now maintenance rather than correction. And the largest risk at this point is regression, which is common and preventable.
Milestone One: Glycaemic Markers Normalised
What this looks like: HbA1c in the lower part of the range, fasting insulin low, triglyceride to HDL ratio favourable, no post-meal symptoms.
What can be removed. Berberine, if it was added for glycaemic control, is a candidate for a removal trial. It has drug-like potency and a substantial interaction profile, and there is no reason to continue it indefinitely if the underlying problem is corrected. Chromium and similar glycaemic support compounds, which had thin evidence to begin with, can go.
What stays. Everything that produced the improvement: training volume, resistance work, food quality, sleep. The markers normalised because of those inputs, and removing them returns the markers.
What to watch. Fasting insulin and triglyceride to HDL ratio are more sensitive than HbA1c to early drift, so they are the better monitoring markers once things are normal. HbA1c is a lagging indicator.
The trap. Attributing the improvement to the supplement and the maintenance to nothing. In most cases the behavioural change did the work and the supplement was a minor term, which becomes apparent in a removal trial.
Milestone Two: Lipids and ApoB at Target
What this looks like: apoB at or below the target appropriate to your risk category, triglycerides normalised.
What can be reduced. If omega-3 was added at 2 to 4 g for elevated triglycerides and triglycerides are now normal, the high dose is no longer needed, and there is a reason to reduce it: atrial fibrillation risk has been reported at higher doses. A maintenance dose or dietary oily fish is reasonable.
What stays indefinitely. Plant sterols and soluble fibre work by ongoing mechanisms, so their effect stops when they stop. These are maintenance rather than correction. The same is true of any lipid-lowering medication, which is a point worth being explicit about, since stopping a statin because the numbers improved is a common and consequential error.
What to watch. ApoB annually, and understand that the exposure is cumulative. Reaching target is not a finish line, it is the beginning of the period during which the lower exposure accrues benefit.
What does not change. Lipoprotein(a). It is genetically determined and stable, so it never becomes a former problem, and it continues to justify keeping the modifiable factors tight.
Milestone Three: Visceral Adiposity Reduced
| At this milestone | Priority shift |
|---|---|
| Waist circumference normalised | From loss to maintenance, which is a different behavioural problem |
| Lean mass at risk from the deficit | Protein and resistance training become the priority |
| Metabolic adaptation present | Expect lower energy requirement; regain is common |
| Energy availability restored | Hormonal markers may improve; re-measure if they were affected |
| Bone density possibly affected | Loading and calcium and vitamin D adequacy, particularly after substantial loss |
This milestone is where the most damage is done, because maintenance is left as an afterthought. Weight regain after loss is the norm rather than the exception, and it is driven partly by physiology, reduced resting metabolic rate and altered appetite signalling, rather than only by behaviour.
What helps: continued resistance training, protein intake maintained rather than reduced, regular self-monitoring, and accepting a lower energy requirement rather than returning to prior intake. The last is the one most often missed.
A specific note for anyone whose loss was medication-assisted: discontinuation is commonly followed by regain, which makes it an ongoing rather than time-limited decision and a clinical conversation rather than a supplement one.
Milestone Four: Blood Pressure Controlled
What this looks like: home readings consistently at target across a week of proper measurement.
What continues. Everything that produced it. Sodium reduction, potassium from food, aerobic exercise, alcohol moderation and weight maintenance all work while they are being done.
What may change clinically. Where blood pressure has fallen substantially through weight loss and exercise and medication is in place, dose reduction is sometimes appropriate, and that is a clinician's decision, not a self-directed one. Stopping antihypertensives independently is a specific and avoidable risk.
What to watch. Home measurement monthly rather than daily, done properly on the occasions it is done. Blood pressure drifts upward with age, weight regain and reduced activity, and it does so silently.
The overlooked check. If blood pressure was resistant and improved with weight loss, sleep-disordered breathing may also have improved. If it was never assessed, it is still worth assessing.
What Never Comes Off
Some things are not corrections and do not have an endpoint.
Training. Aerobic fitness and muscle mass decline when training stops, and the metabolic markers follow. This is the component most often reduced once markers improve, and it is the one that produced them.
Sleep regularity. Its effects on glycaemic control and blood pressure are ongoing.
Food quality and adequate protein. Maintenance mechanisms rather than corrective ones.
Ongoing-mechanism supplements, where they are being used for effect: fibre, plant sterols, and any lipid-lowering medication.
Not smoking. Obviously, and worth stating because relapse is common.
Monitoring itself. The interval can lengthen and the practice should not stop. Drift is silent, and a marker checked annually catches it while a marker checked once does not.
A Reassessment Schedule After Success
Three months after reaching a milestone. Confirm it held. Single readings can be favourable by chance.
Six months. Run removal trials on the corrective components: berberine, high-dose omega-3, anything added for a problem that no longer exists. One at a time, with a re-measurement.
Annually. Full panel. ApoB, HbA1c, fasting insulin, hs-CRP, home blood pressure week, waist circumference, fitness estimate. Compare against your own previous values rather than against reference ranges.
On any life change. New medication, injury interrupting training, a period of poor sleep, significant weight change in either direction, or a new clinical condition. Each is a reason to re-baseline rather than to assume continuity.
The mindset that matters. Metabolic health is a rate rather than a state. Markers reflect what has been happening recently, so a good result describes the last three months rather than a permanent condition. That framing makes maintenance intelligible rather than anticlimactic, and it is the honest description of how this Pillar behaves.
The AEONNN Perspective
This is where AEONNN's Shield thinking has the most immediate practical value, because success creates a new situation that most protocols do not anticipate. A stack built for insulin resistance is mismatched once insulin sensitivity is restored, and the platform runs removal trials on corrective components as a first-class action rather than leaving them in place indefinitely.
The distinction the Insight Protocol maintains here is between corrective and ongoing-mechanism components. Berberine added for glycaemic control is corrective and should be trialled for removal. Fibre and plant sterols work while they are being taken and are maintenance. Conflating the two produces either an indefinitely growing stack or the loss of an effect that was still being produced.
The Population layer flags the two largest risks at this point. Regression after weight loss is the norm rather than the exception and is partly physiological, and lean mass is at risk during and after a deficit, which couples Pillar 4 to Pillar 7. And the platform is explicit that reducing or stopping a statin or an antihypertensive because markers improved is a clinical decision, never a self-directed one.
Pillar Matrix mapping
Metabolic and Cardiovascular Health, Longevity and Biological Age
Database Matrix layers
- Real-Time User Layer (wearable and adherence signals)
- Evidence Layer (PubMed, Cochrane, ClinicalTrials.gov)
- Meta / Consensus Layer (JAMA, BMJ, specialty society positions)
- Population Layer (UK Biobank, NHANES)
Frequently Asked
What should I remove when glycaemic markers normalise?
Corrective components such as berberine and thin-evidence glycaemic support compounds are candidates for a removal trial. The training, food quality and sleep that produced the improvement should stay.
Can I reduce omega-3 once triglycerides are normal?
A high dose added for elevated triglycerides is no longer needed, and atrial fibrillation risk has been reported at higher doses, so reducing to a maintenance dose or dietary oily fish is reasonable.
Do plant sterols and fibre ever come off?
No, if they are being used for effect. They work by ongoing mechanisms, so the effect stops when they stop. They are maintenance rather than correction.
Can I stop a statin if my numbers improved?
Not independently. The improvement is the drug working, and stopping returns the exposure. Any dose change is a clinical decision.
Why is weight regain so common?
It is partly physiological, through reduced resting metabolic rate and altered appetite signalling, rather than only behavioural. Maintaining resistance training, protein intake and accepting a lower energy requirement all help.
Which markers detect early drift best?
Fasting insulin and triglyceride to HDL ratio are more sensitive than HbA1c, which is a lagging indicator. Waist circumference and home blood pressure catch drift early too.
Does lipoprotein(a) ever improve?
No. It is genetically determined and stable, so it never becomes a former problem, and it continues to justify keeping the modifiable factors tight.
Evidence and review
Any dosage ranges cited here reflect the ranges used in published human trials, not personal recommendations. Evidence in this field moves, so this article is reviewed quarterly and carries its last-updated date above. Nothing here is intended as medical advice, and supplementation should be discussed with a qualified clinician, particularly alongside prescribed medication or an existing condition.